Treatment of Recombinant Human Thrombopoietin in Thrombocytopenia after Chemotherapy of Acute Leukemia

Treatment of Recombinant Human Thrombopoietin in Thrombocytopenia after Chemotherapy of Acute Leukemia

After chemotherapy, the patients with acute leukemia often accompany with severe thrombocytopenia, and it is difficult to be prevented and treated. For a long time, platelet transfusion is

always the standard therapeutic method for severe thrombocytopenia with definite efficacy. But the platelets have short storage time, nervous sources, and can occur transfusion

reaction, which restrict its clinical application.

Full-length glycosylation recombinant human thrombopoietin (rhTPO) is mainly used for the treatment in thrombocytopenia caused after tumor chemotherapy. We observed the clinical efficacy and adverse reactions of rhTPO in thrombocytopenia caused after chemotherapy of acute leukemia, and now the report is as below.

Learn more

Uncategorized

Astenic syndrome in a post-covid-19 patient (review and own experience)

Among the symptoms and syndromes that dominate the clinical picture of postcoid syndrome (POST-COVID-19), the signs of asthenia, increased fatigue, excessive exhaustion during normal daily activities, which form asthenic syndrome, are highlighted. For the treatment of postcoid asthenic syndrome, a combination of pathogenetically justified agents has been proposed: podaravone (Xavron), a mixture of L-arginine and...
Uncategorized

” Long-haulers “: patients with post-covid syndrome in routine clinical practice

At the beginning of the COVID 19 pandemic, SARS-CoV 2 disease was thought to be transient (like most respiratory viral infections). The World Health Organization later reported that the duration of a new coronavirus disease from the onset of the first symptoms to mild clinical recovery is ≈2 weeks, and in severe or moderate cases,...